Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ariadna Tibau

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Cancer Treatment Reviews|September 20, 2021
The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysisDor Reuven Dabush, Daniel Shepshelovich, Tzippy Shochat, et al.
Cancer Treatment Reviews|October 31, 2020
National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional studyTal Etan, Eitan Amir, Ariadna Tibau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2018
Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled TrialsDaniel Shepshelovich, Ariadna Tibau, Hadar Goldvaser, et al.
JCO Oncology Practice|June 22, 2022
Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and AustraliaThomas J Hwang, Aaron S Kesselheim, Ariadna Tibau, et al.
JAMA Oncology|March 5, 2016
Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug AdministrationAriadna Tibau, Alberto Ocana, Geòrgia Anguera, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value AssessmentBishal Gyawali, Thomas J Hwang, Kerstin Noelle Vokinger, et al.
Scientific Reports|December 9, 2022
Association between control group therapy and magnitude of clinical benefit of cancer drugsConsolacion Molto, Ariadna Tibau, Aida Bujosa, et al.
Cancer Treatment Reviews|December 8, 2023
Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic reviewShlomit Strulov Shachar, Yasmin Korzets, Daniel Shepshelovich, et al.
Eclinicalmedicine|July 21, 2025
Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort studyAriadna Tibau, Edward R Scheffer Cliff, Alejandra Romano, et al.
JAMA Network Open|March 26, 2025
Factors in Time to Full Approval or Withdrawal for Anticancer Medicines Granted Accelerated Approval by the FDAAriadna Tibau, Thomas J Hwang, Alejandra Romano, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Cancer Treatment Reviews|September 20, 2021
The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysisDor Reuven Dabush, Daniel Shepshelovich, Tzippy Shochat, et al.
Cancer Treatment Reviews|October 31, 2020
National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional studyTal Etan, Eitan Amir, Ariadna Tibau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2018
Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled TrialsDaniel Shepshelovich, Ariadna Tibau, Hadar Goldvaser, et al.
JCO Oncology Practice|June 22, 2022
Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and AustraliaThomas J Hwang, Aaron S Kesselheim, Ariadna Tibau, et al.
JAMA Oncology|March 5, 2016
Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug AdministrationAriadna Tibau, Alberto Ocana, Geòrgia Anguera, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value AssessmentBishal Gyawali, Thomas J Hwang, Kerstin Noelle Vokinger, et al.
Scientific Reports|December 9, 2022
Association between control group therapy and magnitude of clinical benefit of cancer drugsConsolacion Molto, Ariadna Tibau, Aida Bujosa, et al.
Cancer Treatment Reviews|December 8, 2023
Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic reviewShlomit Strulov Shachar, Yasmin Korzets, Daniel Shepshelovich, et al.
Eclinicalmedicine|July 21, 2025
Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort studyAriadna Tibau, Edward R Scheffer Cliff, Alejandra Romano, et al.
JAMA Network Open|March 26, 2025
Factors in Time to Full Approval or Withdrawal for Anticancer Medicines Granted Accelerated Approval by the FDAAriadna Tibau, Thomas J Hwang, Alejandra Romano, et al.
Pageof 5